Skip to content
    IQV
    Earnings call· Dec 2024(Q4 FY24)

    IQVIA HOLDINGS INC. IQV

    Feb 6, 2025 Source

    Executive summary

    IQVIA Q4 FY24 — Strong Q4 Performance and Reaffirmed 2025 Guidance Amidst Macro Headwinds

    IQVIA delivered solid Q4 FY24 results, with revenue and EPS exceeding expectations, driven by strong TAS recovery and robust R&DS bookings despite significant macro and industry headwinds. The company reaffirmed its full-year 2025 guidance, anticipating continued TAS growth and a gradual stabilization in R&DS as large pharma reprioritizations largely conclude, while actively managing costs and leveraging AI for efficiency.

    Highlights

    5

    • Q4 revenue grew 4.5% at constant currency excluding COVID, exceeding guidance.

    • Adjusted diluted EPS increased 9.9% year-over-year to $3.12 in Q4.

    • Record quarterly free cash flow of $721 million, contributing to $2.1 billion for the full year (up 41%).

    • Net new R&DS bookings over $2.5 billion in Q4, leading to a $31.1 billion backlog (up 5.5% constant currency).

    • Successfully renewed all large pharma strategic partnerships and expanded scope with several clients.

    Concerns

    4

    • Elevated cancellations in Q4, nearly 50% higher than the average of the previous three years, due to portfolio reprioritizations.

    • Continued volatility in R&DS demand expected for another one to two quarters.

    • Stranded costs associated with two delayed mega-trials impacting gross margin.

    • Foreign currency headwinds of approximately 150 basis points expected for FY25.

    Guidance & targets

    12
    CategoryTargetConfidence
    Full Year 2025 Revenue Growth (constant currency ex-COVID)
    4% to 7%
    high materiality
    High
    Full Year 2025 Adjusted EBITDA Margin Expansion
    up to 20 basis points
    medium materiality
    High
    Full Year 2025 Adjusted Diluted EPS Growth
    5% to 9%
    high materiality
    High
    Full Year 2025 Total Revenue
    $15.725 billion and $16.125 billion
    high materiality
    High
    Full Year 2025 Adjusted EBITDA
    $3.765 billion to $3.885 billion
    high materiality
    High
    Full Year 2025 Adjusted Diluted EPS
    $11.70 to $12.10
    high materiality
    High
    Full Year 2025 TAS Revenue Growth (constant currency)
    5% to 7%
    medium materiality
    High
    Full Year 2025 R&DS Revenue Growth (constant currency ex-COVID)
    4% to 6%
    medium materiality
    High
    Full Year 2025 CSMS Revenue
    approximately $700 million
    low materiality
    High
    Q1 2025 Revenue
    $3.740 billion and $3.790 billion
    medium materiality
    High
    Q1 2025 Adjusted EBITDA
    $870 million and $890 million
    medium materiality
    High
    Q1 2025 Adjusted Diluted EPS
    $2.60 and $2.70
    medium materiality
    High

    Segment performance

    3
    SegmentRevenueYoYQoQMargin
    Technology & Analytics Solutions
    Growth trajectory improved throughout 2024, finishing H2 with high single-digit growth driven by strong mid-single-digit organic growth. TAS is a short-cycle business and serves as a leading indicator for industry recovery.
    Real world growth: double-digit (Q4)Full year revenue growth: 5.1% reported, 5.7% constant currency, 6.5% ex-COVID constant currency
    		$1.658 billion8.3% reported, 9.5% constant currency——
    R&D Solutions
    Strong bookings helped mitigate elevated cancellations. Successfully renewed all large pharma strategic partnerships. Expects lower growth in H1 2025, improving sequentially.
    Net new bookings: over $2.5 billion (Q4)Backlog: $31.1 billion (Dec 31)Backlog growth: 4.4% YoY reported, 5.5% YoY constant currencyFull year revenue growth: 1.6% reported, 2% constant currency, over 5% ex-COVID constant currency
    		$2.123 billion-1.3% reported, -1% constant currency——
    Contract Sales and Medical Solutions
    Flattish year-over-year expected for FY25.
    Full year revenue: $718 millionFull year revenue growth: -1.2% reported, 1.4% constant currency
    		$177 million-4.8% reported, -3.2% constant currency——

    Operational metrics

    35
    Revenue growth (ex-FX, ex-COVID)
    4.5%
    Q4 FY24

    Revenue came in above the high end of guidance range.

    Reported Revenue growth
    2.3%
    Q4 FY24

    Reported revenue growth for the fourth quarter.

    Reported Revenue growth
    2.8%
    FY24

    Full year reported revenue growth.

    Constant Currency Revenue growth
    3.4%
    FY24

    Full year constant currency revenue growth.

    Adjusted Net Income
    $564 million
    Q4 FY24

    Adjusted net income for the fourth quarter.

    Adjusted Net Income
    $2.42 billion
    FY24

    Adjusted net income for the full year.

    Capital expenditure
    $164 million
    Q4 FY24

    Capital expenditure for the fourth quarter.

    Adjusted EBITDA
    $996 millionup 3.1%
    Q4 FY24

    Adjusted EBITDA for the fourth quarter.

    Adjusted EBITDA
    $3.684 billionup 3.2% year-over-year
    FY24

    Full year adjusted EBITDA.

    Adjusted Diluted EPS
    $3.12up 9.9% year-over-year
    Q4 FY24

    Adjusted diluted EPS for the fourth quarter.

    Adjusted Diluted EPS
    $11.13
    FY24

    Full year adjusted diluted EPS.

    Cash and cash equivalents
    $1.702 billion
    Dec 31

    Balance as of December 31.

    Gross debt
    $13.983 billion
    Dec 31

    Balance as of December 31.

    Net debt
    $12.281 billion
    Dec 31

    Balance as of December 31.

    Net leverage ratio
    3.33x
    Dec 31

    Net leverage ratio at year-end.

    Share repurchases
    $1.150 billion
    Q4 FY24

    Share repurchases executed in the fourth quarter.

    Share repurchases
    $1.350 billion
    FY24

    Total share repurchases for the full year.

    Remaining share repurchase authorization
    $3 billion
    current

    Board of Directors replenished authorization by $2 billion, increasing total remaining authorization.

    COVID-related revenue
    $10 milliondown $50 million vs Q4 2023
    Q4 FY24

    COVID-related revenue for the fourth quarter.

    COVID-related revenue
    $110 million
    FY24

    Total COVID-related revenue for the full year.

    Acquisition contribution to revenue growth
    2 points
    Q4 FY24

    Contribution from acquisitions to Q4 constant currency growth.

    Adjusted EBITDA margin expansion
    20 bps
    Q4 FY24

    Driven by revenue growth and ongoing cost management discipline.

    Biotech funding
    over $100 billion44% higher than 2023
    FY24

    Record funding, excluding 2020 and 2021. Compared to $71 billion in 2023.

    Biotech funding
    $71 billion
    FY23

    Biotech funding in the previous year.

    RFP flow growth
    mid-single digits
    Q4 FY24

    Leading indicator for R&DS demand environment.

    Cancellations
    almost 50% highervs average of previous 3 years
    FY24

    Elevated cancellations due to portfolio reprioritizations.

    Gross new bookings
    up mid-single digitsvs 2023
    FY24

    Offsetting the higher level of cancellations.

    Stranded costs
    —
    Q4 FY24

    Costs associated with two delayed mega-trials affecting gross margin.

    Innovations introduced
    60
    FY24

    Includes 39 AI-enabled applications.

    AI-enabled applications introduced
    39
    FY24

    Part of the 60 innovations introduced.

    Pharma partnerships
    22
    current

    IQVIA now has partnerships with 22 of the top 25 pharma companies.

    Number of CROs
    4,000
    current

    Stated by CEO in Q&A to highlight market fragmentation.

    Drug approvals
    55
    FY23

    Record year for drug approvals.

    Drug approvals
    about 50
    FY24

    Good year for drug approvals.

    Average quarterly cancellations
    $0.5 billion
    historical average

    Historical average, with quarters ranging from $300 million to $600 million.

    Industry KPIs

    6
    MetricValueDetails
    FCF conversion ROIC104%%
    Revenue EPS guidancereaffirmed
    Pricing price realizationmore difficult
    M a contribution synergies100 to 150 basis pointsbps
    Clinical research cro bookingsover $2.5 billionUSD
    Segment organic revenue growthmid-single-digit organic growth%

    Product announcements

    3
    ProductTypeDetails
    IQVIA AI Assistantlaunch
    Patient Relationship Managerlaunch
    Digital Business Expansion (Europe)expansion

    Deals & partnerships

    16
    World Health Organization (WHO)Helped control Poliovirus outbreaks in Africa.

    Part of IQVIA's advancements in global health business.

    Coalition for Epidemic Preparedness Innovations (CEPI)Collaborated in Rwanda to respond to a Marburg virus disease outbreak.

    Part of IQVIA's advancements in global health business.

    Large biotech clientSelected to expedite a vaccine trial for mpox in Sub-Saharan Africa.

    Addressing a critical outbreak and unmet medical needs. Part of global health business achievements.

    Top 10 pharma clientAwarded strategic partnership to deliver omnichannel marketing solutions.

    Utilizes analytics, information, technology, and commercial outsourcing capability. Example of integrated solutions.

    Biotech companyPartnering to launch a new treatment for ovarian cancer.

    Leverages IQVIA's comprehensive commercial capabilities and expertise to execute regulatory process, launch, and commercial activities.

    EVP clientAsked IQVIA to support launching a new cell therapy for a severe pediatric condition.

    Providing full comprehensive commercial infrastructure, including field sales, medical, commercial communications, compliance, and OCE.

    Large pharma clientEngaged IQVIA to simplify data management by integrating diverse sources from over 30 countries.

    Streamlining operations and centralizing global information into a single standardized system.

    Top 10 pharma clientUsing advanced AI to support demonstrating efficacy for gastric cancer treatment and gain approval in new markets.

    Leveraging real-world evidence solutions.

    Top 10-15 pharma clientChose IQVIA to help track disease and treatment efficacy in support of various regulatory submissions in Europe.

    Leveraging real-world evidence solutions.

    Top 5 pharma clientSelected IQVIA to conduct a complex full-service Phase III study addressing asthma and COPD patients.

    R&DS win, highlighting capabilities across therapeutic areas.

    Top 30 pharmaAwarded a large full-service global Phase III breast cancer study.

    R&DS win.

    Top 10 pharma clientAwarded a large FSP contract, displacing 2 large long-time incumbent CROs.

    R&DS win, demonstrating ability to displace incumbents.

    Undisclosed MedTech clientAwarded a study to evaluate a novel medical device specifically targeting a cardiovascular condition.

    MedTech R&DS win.

    Biotech clientAwarded a critical Phase III oncology study.

    Based on strong data-driven approach and ability to manage global complex trials efficiently.

    Biotech clientAwarded a global full-service study for progressive pulmonary fibrosis disease, involving nearly 1,000 patients in 26 countries.

    Won based on global footprint and therapeutic expertise.

    Undisclosed Biotech clientAwarded a Phase II trial for rare CNS conditions with limited previous research.

    R&DS win.

    Risks & headwinds

    5
    Impact of Inflation Reduction Act (IRA)Persisted through 2024

    Led to delayed customer decision-making, reduced discretionary spend, and portfolio reprioritizations.

    Mitigation: Management believes bulk of reprioritization is complete; new administration may adjust aspects of IRA.

    Macroeconomic environmentPersisted through 2024

    Geopolitical unrest, continued high interest rates, inflation, foreign currency headwinds, political election uncertainty.

    Mitigation: Strong operational discipline, cost management, and leveraging IT/AI for efficiency.

    Elevated R&DS cancellationsQ4 2024, with volatility expected for 'another quarter or two' in 2025.

    Q4 cancellations 'not far from $1 billion'; FY24 cancellations almost 50% higher than average of previous 3 years.

    Mitigation: Strong gross new bookings (up mid-single digits in FY24) offsetting cancellations; belief that bulk of portfolio reprioritization is complete.

    Stranded costs from delayed mega-trialsThrough 2025

    Affecting gross margin.

    Mitigation: Will manage costs; trials expected to resume in H2 2025.

    Foreign currency headwindsFY25

    Approximately 150 basis points headwind versus 2024 for FY25.

    Mitigation: Guidance incorporates this assumption.

    What to watch in Q1 FY25

    5

    R&DS demand volatility

    Next quarter (Q1 2025) and Q2 2025.
    CurrentElevated cancellations in Q4 2024 (nearly $1B), FY24 cancellations almost 50% higher than prior 3-year average.
    TargetStabilization of demand and reduction in cancellation levels.

    Why it matters

    Indicates the completion of large pharma portfolio reprioritizations and the underlying health of the R&DS business, impacting future revenue growth.

    On the R&DS side, we still have some volatility, so we might see another quarter or 2 of fluctuating demand and elevated cancellations. But we think the bulk of the portfolio reprioritization at large pharma has been completed.

    Q&A highlights

    6

    Asked for more color on Q4 operating environment relative to expectations, particularly regarding vendor reassessments and portfolio reprioritizations, and the status of the two delayed mega-trials.

    Ari Bousbib stated that the operating environment was largely as anticipated, with 2/3 to 3/4 of large pharma reprioritizations completed, but acknowledged continued volatility for 1-2 more quarters. The two delayed trials are still on track for late 2025, causing some stranded costs.

    “We think the bulk of the cancellation, the reprioritization has occurred. We said then I'll repeat now, we're still going to have 1 to 3 quarters of some volatility.”

    asked by Shlomo Rosenbaum · answered by Ari Bousbib

    2 min read6 chapters

    Detailed Narrative

    01

    Industry Headwinds and Resilience

    IQVIA navigated a challenging 2024 marked by the Inflation Reduction Act's impact on customer decision-making, geopolitical unrest, high interest rates, and FX headwinds🌐. Despite these, the company achieved solid full-year results, with 5.5% constant currency revenue growth (ex-COVID) and 9% adjusted EPS growth, positioning itself as an outperformer in the industry. Management noted that very few companies in their broader sector achieved positive growth.

    02

    R&DS Performance and Outlook

    The R&DS business secured over $2.5 billion in net new bookings in Q4, contributing to an end-of-year backlog of $31.1 billion, up 5.5% at constant currency. While cancellations were elevated (nearly 50% higher than the prior three-year average for 2024), gross bookings were stronger. Management expects continued volatility for 1-2 more quarters but believes the bulk of large pharma portfolio reprioritization is complete, supported by mid-single-digit RFP flow growth in Q4, with EBP segment showing even higher growth.

    03

    TAS Segment Recovery and Innovation

    The TAS segment's growth trajectory materialized as anticipated, with low single-digit growth in H1 and a ramp-up to high single-digit growth in H2, exceeding expectations. Real-world evidence solutions returned to double-digit growth in Q4. IQVIA introduced 60 innovations in 2024, including 39 AI-enabled applications like IQVIA AI Assistant and patient relationship manager, demonstrating a focus on integrated, AI-driven solutions and expanding its digital business into Europe.

    04

    Strategic Partnerships and Global Health Initiatives

    IQVIA successfully renewed all large pharma strategic partnerships in 2024, expanding scope and displacing incumbents, now partnering with 22 of the top 25 pharma companies. The company also made significant advancements in global health, assisting the WHO with Poliovirus outbreaks and CEPI with Marburg virus, and expediting an mpox vaccine trial in Sub-Saharan Africa, highlighting its role in public health crises.

    05

    Financial Discipline and Capital Allocation

    The company achieved 20 bps of adjusted EBITDA margin expansion in Q4 and generated a record $721 million in free cash flow for the quarter, bringing the full-year total to over $2.1 billion, up 41%. IQVIA repurchased $1.15 billion of shares in Q4, totaling $1.35 billion for the year, and the Board authorized an additional $2 billion for share repurchases, increasing total authorization to $3 billion, demonstrating commitment to shareholder returns.

    06

    AI Collaboration and Future Growth Drivers

    A collaboration with NVIDIA was announced to advance agentic AI solutions in healthcare and life sciences, aiming to transform clinical trials and commercial processes by introducing AI agents as digital companions. This initiative, alongside integrated solutions combining information, analytics, and services, is enabling larger, longer-term deals and is expected to drive future growth and efficiency.

    AI-generated summary of the company’s earnings call. Not investment advice.